Biomarin Pharmaceutical (BMRN) Shares Outstanding (Weighted Average) (2009 - 2026)

Biomarin Pharmaceutical has disclosed Shares Outstanding (Weighted Average) across 18 years of filings, most recently posting $192.5 million for Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 0.8% year-over-year to $192.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.5 million (up 0.8% YoY) and the FY2025 annual result came in at $191.8 million, up 0.93% from the prior year.
• Shares Outstanding (Weighted Average) held at $192.5 million in Q1 2026, from $191.8 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $192.5 million in Q1 2026 and troughed at $184.0 million in Q1 2022.
• A 5-year average of $188.6 million and a median of $188.9 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) advanced 1.74% — and 2026, when it grew 0.8%.
• Tracing BMRN's Shares Outstanding (Weighted Average) over 5 years: stood at $185.3 million in 2022, then increased by 1.39% to $187.8 million in 2023, then gained by 1.17% to $190.0 million in 2024, then gained by 0.93% to $191.8 million in 2025, then advanced by 0.37% to $192.5 million in 2026.
• Business Quant data shows BMRN's Shares Outstanding (Weighted Average) at $192.5 million in Q1 2026, $191.8 million in Q4 2025, and $191.6 million in Q3 2025.